Evidence map›Paper›PMID 41465211›Full record

ReviewInternational journal of molecular sciences2025

Overcoming Antibiotic Resistance and Treating Bacterial Infections with Biological Nanoparticles.

Boris Ponomarev, Natalia Ponomareva, Artyom Kachanov, Konstantin Evmenov, Sergey Brezgin, Anastasiia Kostyusheva, Vladimir Chulanov, Peter Timashev, Dmitry Kostyushev, Alexander Lukashev

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Boris PonomarevLaboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, Sechenov University, Moscow 119435, Russia.
Natalia PonomarevaLaboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, Sechenov University, Moscow 119435, Russia.
Artyom KachanovLaboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, Sechenov University, Moscow 119435, Russia.ORCID 0009-0000-7354-7240
Konstantin EvmenovLaboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, Sechenov University, Moscow 119435, Russia.ORCID 0000-0001-6183-6504
Sergey BrezginLaboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, Sechenov University, Moscow 119435, Russia.ORCID 0000-0003-4792-0739
Anastasiia KostyushevaLaboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, Sechenov University, Moscow 119435, Russia.
Vladimir ChulanovEngelhardt Institute of Molecular Biology, Russian Academy of Science, Moscow 119991, Russia.ORCID 0000-0001-6303-9293
Peter TimashevInstitute for Regenerative Medicine, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.
Dmitry KostyushevLaboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, Sechenov University, Moscow 119435, Russia.ORCID 0000-0002-1851-7441
Alexander LukashevMartsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, Sechenov University, Moscow 119435, Russia.

Funding

Ministry of Science and Higher Education of the Russian Federation 075-15-2024-640
6 · The paper itself

Abstract

For over eight decades, antibiotics have been the cornerstone of treating bacterial infections. However, the rapid rise of antibiotic-resistant pathogens has created an urgent need for alternative therapeutic strategies. Advances in nanotechnology offer a promising solution through the development of bio-derived nanoparticles. This broad class includes extracellular vesicles such as exosomes and bacterial outer membrane vesicles (OMVs), as well as bioengineered cell membrane-coated nanoparticles (CMNPs) that combine synthetic cores with natural membranes from diverse source cells. These particles possess unique physicochemical and biological properties, such as intrinsic bioactivity, biocompatibility, and structural versatility, that can be harnessed for antimicrobial therapy. This review synthesizes recent progress in the design, characterization, and application of biological nanoparticles for combating bacterial infections. We place particular emphasis on their mechanisms of action, therapeutic potential, and key research directions that could accelerate their translation into clinical use.

Indexed as

Anti-Bacterial AgentsBacterial InfectionsDrug Resistance, BacterialNanoparticlesAnimalsBacteriaExtracellular VesiclesHumansAnti-Bacterial Agentsantibiotic resistancedrug deliveryexosomesextracellular vesiclesouter membrane vesicles

Identifiers

PMID41465211
PMCPMC12732347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.